PB2087: EFFICACY OF A 3RD COVID VACCINE, INCLUDING DURING A BTKI PAUSE, IN INDIVIDUALS WITH WALDENSTRÖM MACROGLOBULINEMIA AND FOLLICULAR LYMPHOMA

Documenti analoghi

• The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
  di: Obada Ababneh, et al.
  Pubblicazione: (2022-05-01)
• PB2087: EFFICACY OF A 3RD COVID VACCINE, INCLUDING DURING A BTKI PAUSE, IN INDIVIDUALS WITH WALDENSTRÖM MACROGLOBULINEMIA AND FOLLICULAR LYMPHOMA
  di: K. Rankin, et al.
  Pubblicazione: (2022-06-01)
• CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
  di: Morgane Brocard, et al.
  Pubblicazione: (2026-03-01)
• Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
  di: Benjamin M. Heyman, et al.
  Pubblicazione: (2025-02-01)
• Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)
  di: Maroun Bou Zerdan, et al.
  Pubblicazione: (2022-01-01)